[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554146":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":44,"responsibleParty":63,"collaborators":65,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":85,"sex":91,"minAge":92,"maxAge":26,"enrollmentInfo":93,"targetDuration":26,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":47,"whyStopped":26,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Unity Health Toronto","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Whole Blood (WB)","EXPERIMENTAL","The use of Whole Blood (WB), leukocytes reduced is indicated for treatment of patients with clinically significant bleeding and have low anti-A and anti-B titres.\n\nPatients will be administered up to 2 units of whole blood administered via either intravenous (IV) or intraosseous (IO) route, according to standard practice at Ornge AAS.",[13],"Biological: Whole Blood",{"label":15,"type":16,"description":17,"interventionNames":18},"Red Blood Cells and Plasma","ACTIVE_COMPARATOR","The control arm will consist of 2 units of RBC and 2 units of plasma (dependent on the standard practice of the Ornge AAS).\n\nRBC and plasma may be administered via either the intravenous (IV) or intraosseous (IO) route, according to standard clinical practice at Ornge AAS.",[19],"Biological: RBC + plasma",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BIOLOGICAL","Whole Blood","2 units of whole blood administered by Ornge AAS",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"RBC + plasma","2 units of RBC + 2 units of plasma administered by Ornge AAS",[15],[32],{"name":33,"affiliation":5,"role":34},"Brodie Nolan, MD MSc","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"SWiFT Canada","CONTACT","437 778 2260","swift@unityhealth.to",{"name":42,"role":38,"phone":39,"phoneExt":26,"email":43},"Melissa McGowan","melissa.mcgowan@unityhealth.to",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":26,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Ornge Air Ambulance","RECRUITING","Toronto","Ontario","Canada","CA",{"type":53,"coordinates":54},"Point",[55,56],-79.39864,43.70643,{"lat":56,"lon":55},[59,62],{"name":33,"role":38,"phone":60,"phoneExt":26,"email":61},"1.800.251.6943","bnolan@ornge.ca",{"name":33,"role":34,"phone":26,"phoneExt":26,"email":26},{"type":64,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[66,69,71,73,75,77,79,81],{"name":67,"class":68},"Veteran Affairs Canada","UNKNOWN",{"name":70,"class":68},"Ornge",{"name":72,"class":6},"Canadian Blood Services",{"name":74,"class":6},"Sunnybrook Health Sciences Centre",{"name":76,"class":6},"Hamilton Health Sciences Corporation",{"name":78,"class":6},"London Health Sciences Centre",{"name":80,"class":6},"Kingston Health Sciences Centre",{"name":82,"class":6},"Health Sciences North","100554146","swift-canada-study-of-whole-blood-in-frontline-trauma-100554146",false,"NCT06495294","SWiFT Canada (Study of Whole Blood in Frontline Trauma)","SWiFT Canada (Study of Whole Blood in Frontline Trauma): A Pilot Randomized Controlled Trial Assessing Prehospital Whole Blood Versus Component Therapy in Traumatic Hemorrhage","SWiFTCanada","Inclusion Criteria:\n\n* Patient who has suffered a traumatic injury\n* Attended by a participating Ornge AAS clinical team\n* Requires prehospital blood transfusion to treat major traumatic hemorrhage\n\nExclusion Criteria:\n\n* Pediatric (age \\\u003C16 or transported to pediatric trauma centre \\[if age unknown\\])\n* No intravenous or intraosseous access (should be assessed prior to opening box)\n* Knowledge that patient will object to being given blood transfusion for any reasons\n* Blood already administered on-scene, prior to arrival of the participating Ornge AAS","ALL","16 Years",{"count":94,"type":95},60,"ESTIMATED","INTERVENTIONAL",[98],"NA","Traumatic injuries affect people of all ages, races, and socioeconomic backgrounds. The Global Burden of Disease study showed that globally in 2019, there were more than 4.4 million deaths due to injury. Furthermore, unintentional injuries are the leading cause of death for people aged 5-29 years worldwide. Uncontrolled bleeding accounts for a significant proportion of these deaths, with approximately 20% occurring in the first 24 hours and 40% occurring within the first 30 days.\n\nBlood transfusion is a life-saving treatment in the management of bleeding patients until bleeding is controlled in hospital, typically delivered through different blood components (red blood cells, plasma and platelets). These components are derived from a whole blood donation and are stored in separate bags (units). There are challenges in carrying separate blood products, such as additional weight in kit bags, and transfusing multiple blood products at the scene can delay transport to hospital.\n\nIn Ontario, Ornge Air Ambulance carries red blood cells and plasma to transfuse prehospital. However, a prehospital transfusion strategy has not been established and practice varies across the Canadian setting, and more broadly across the world.\n\nThis trial aims to investigate if carrying and transfusing two units of whole blood instead of four units (two red blood cells and two plasma) is feasible and leads to better outcomes for patients.",[101],"Trauma",[103,104,105,106],"prehospital","major hemorrhage","transfusion","emergency medicine","2026-04-29",{"date":109,"type":110},"2026-05-06","ACTUAL",{"date":112,"type":110},"2024-12-16",{"date":114,"type":95},"2027-03",{"name":5,"class":6},1]